Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy

Annals of Nuclear Medicine

Volumn 19, Issue 4, 2005, Pages 297-308

  Nakajo, Masayuki ^a   Tsuchimochi, Shinsaku ^a   Tanabe, Hiroaki ^a   Nakabeppu, Yoshiaki ^a   Jinguji, Megumi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

131I; Graves' disease; Hyperthyroidism; Thyroid; Thyroid hormone

Indexed keywords

IODINE 131; LIOTHYRONINE; RADIOACTIVE IODINE; THYROID HORMONE; THYROXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EUTHYROIDISM; FEMALE; FREE THYROXINE INDEX; GRAVES DISEASE; HORMONAL REGULATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 23344439596     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02984622     Document Type: Article

References (52)

1. Freitas JE. The role of nuclear medicine in the management of Graves' disease. Q J Nucl Med 1999; 43: 297-306.
2. Safa AM, Skillern PG. Treatment of hyperthyroidism with a large initial dose of sodium iodide I 131. Arch Intern Med 1975; 135: 673-675.
3. Beierwaltes WH. The treatment of hyperthyroidism with iodine-131. Semin Nucl Med 1978; 8: 95-103.
4. 131I therapy for hyperthyroidism in relation to immunologic parameters. Acta Radiol Oncol 1980; 19: 449-454.
5. Davies TF, Platzer M, Farid NR. Prediction of therapeutic response to radioactive iodine in Graves' disease using TSH-receptor antibodies and HLA-status. Clin Endocrinol 1982; 16: 183-191.
6. 131I in the treatment of hyperthyroidism: Results of a prospective study. Am J Med Sci 1969; 257: 382-387.
7. Harbert JC. Radionuclide therapy of hyperthyroidism. In: Harbert JC, ed. Nuclear Medicine therapy. Stuttgart; Thiem, 1987: 1-36.
8. Kaplan MM, Meier DA, Dworkin HJ. Treatment of hyperthyroidism with radioactive iodine. Endocrinol Metab Clin North Am 1998; 27: 205-223.
9. 131I therapy for Graves' disease. N Engl J Med 1984; 311: 426-432.
10. Hoskin PJ, McCready VR, Harmer CL. Low-dose radioiodine given six-monthly in Graves' disease. J Roy Soc Med 1985; 78: 893-898.
11. Ratcliffe GE, Fogelman I, Maisey MN. The evaluation of radioiodine therapy for thyroid patients using a fixed-dose regime. Br J Radiol 1986; 59: 1105-1107.
12. Danaci M, Feek CF, Notghi A, Merrick MV, Padfield PL, Edwards CRW. 131-I radioiodine therapy for hyperthyroidism in patients with Graves' disease, uninodular goitre and multinodular goitre. NZ Med J 1988; 101: 784-786.
13. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine: Results of a prospective randomized study. Thyroid 1997; 7: 247-251.
14. Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab 2001; 86: 3611-3617.
15. Howarth D, Epstein M, Lan L, Tan P, Boocker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001; 28: 1489-1495.
16. Reynolds LR, Kotchen TA. Antithyroid drugs and radioactive iodine-fifteen years' experience with Graves' disease. Arch Intern Med 1979; 139: 651-653.
17. Velkeniers B, Cytryn R, Vanhaelst L, Jonckheer MH. Treatment of hyperthyroidism with radioiodine: Adjunctive therapy with antithyroid drugs reconsidered. Lancet May 21, 1988, 1127-1129.
18. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E, et al. A reappraisal of the role of Methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest 1990; 13: 513-520.
19. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 685-687.
20. Cooper DS. Treatment of thyrotoxicosis: Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text. Braverman LE, Utiger RD (eds), Philadelphia; Lippincott-Raven, 1996: 713-734.
21. Nordyke RA, Gilbert FI Jr. Optical iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med 1991; 32: 411-416.
22. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinarts P, Willmes K, et al. Success rate of radioiodine therapy in Graves' disease: The influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84: 1229-1233.
23. Calegaro JUM, Gomes ED, Bae SH, Ulyssea R, Casulari KA. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration. Panninerva Med 2000; 42: 241-245.
24. 131I in treatment of Graves' disease. J Roy Soc Med 1985; 78: 197-202.
25. Shafer RB, Nuttall FQ. Acute changes in thyroid function in patients treated with radioactive iodine. Lancet 1975; 2: 635-637.
26. 131I ablation for Graves' disease. J Clin Endocrinol Metab 2001; 86: 3016-3021.
27. Burch HB, Solomon BL, Wartofsky, Burman KD. Discontinuing antithyroid drug therapy before ablation with radioiodine in Graves' disease. Ann Intern Med 1994; 121: 553-559.
28. 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med 1999; 55: 215-221.
29. Tamagna EI, Levine GA, Hershman JM. Thyroid-hormone concentrations after radioiodine therapy for hyperthyroidism. J Nucl Med 1979; 20: 387-391.
30. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J Clin Endocrinol Metab 1999; 84: 4012-4016.
31. 131I treatment of thyrotoxicosis. Eur J Nucl Med 1980; 5: 199-203.
32. Bellabarba D, Bénard B, Langlois M. Pattern of serum thyroxine, triiodothyronine and thyrotrophin after treatment of thyrotoxicosis. Clin Endocrinol 1972; 1: 345-353.
33. Kusakabe K, Nakano K, Maki M, Ohta Y, Hiroe M, Shigeta A, et al. Long-term follow-up study of I-131 therapy for Graves' disease-Index associated with late-onset hypothyroidism-. KAKU IGAKU (Jpn J Nucl Med) 1990; 27: 333-340.
34. Breiman RS, Beck JW, Korobkin M, Glenny R, Akwari OE, Heaston DK, et al. Volume determinations using computed tomography. AJR 1982; 138: 329-333.
35. Hermans R, Bouillon R, Laga K, Delaere PR, De Foer B, Marchai G, et al. Estimation of thyroid gland volume by spiral computed tomography. Eur Radiol 1997; 7: 214-216.
36. Nakajo M, Tanabe H, Tsuchimochi S, Nakamura H, Jinguji M. Estimation of small thyroid phantom volume by computed tomography. Jpn J Tomogr 2004; 31: 140-146.
37. Atkinson S, McGregor AM, Kendall-Tailor P, Peterson MM, Smith BR. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins. Clin Endocrinol 1982; 16: 537-543.
38. 131I) therapy for hyperthyroid Graves' disease. Endocrinol Japan 1991; 38: 429-433.
39. Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1998; 83: 40-46.
40. Cooper DS. Treatment of thyrotoxicosis. In: Werner & Ingbar's The Thyroid. A Fundamental and Clinical text. Braverman LE, Utiger RD (eds), Philadelphia; Lippicott Williams & Wilkins, 2000: 691-715.
41. Dobyns BM, Vickery AL, Maloof F, Chapman EM. Functional and histologic effects of therapeutic doses of radioactive iodine on the thyroid of man. J Clin Endocrinol Metab 1953; 13: 548-567.
42. 131I) of hyperthyroidism. In: Nuclear Medicine Annual 1982, Freeman LM, Weisemann HS (eds), New York; Raven Press, 1982:265-290.
43. 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 1997; 82: 2926-2930.
44. Dorfman S, Young RL, Carretta RF. Transient hypothyroidism. Arch Intern Med 1977; 137: 256-257.
45. MacFarlane IA, Shalet SM, Beardwell CG, Khara JS. Transient hypothyroidism after iodine-131 treatment for thyrotoxicosis. Br Med J 1979; 2: 421.
46. Sawers JSA, Toft AD, Irvine WJ, Brown NS, Seth J. Transient hypothyroidism after iodine-131 treatment of thyrotoxicosis. J Clin Endocrinol Metab 1980; 50: 226-229.
47. Connell JMC, Hilditch TE, McCruden DC, Alexander WD. Transient hypothyroidism following radioiodine therapy for thyrotoxicosis. Br J Radiol 1983; 56: 309-313.
48. Gómez N, Gómez JM, Orti A, Gavaldà L, Villabona C, Leyes P, et al. Transient hypothyroidism after iodine-131 therapy for Graves' disease. J Nucl Med 1995; 36: 1539-1542.
49. Aizawa Y, Yoshida K, Kaise N, Fukuzawa H, Kiso Y, Sayama N, et al. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis. Clin Endocrinol 1997; 46: 1-5.
50. Davis JRE, Black EG, Sheppard MC. Evaluation of a sensitive chemiluminescent assay for TSH in the follow-up of treated thyrotoxicosis. Clin Endocrinol 1987; 27: 563-570.
51. Davis PH, Franklyn JA, Daykin J, Sheppard MC. The significance of TSH values measured in a sensitive assay in the follow-up of hyperthyroid patients treated with radioiodine. J Clin Endocrinol Metab 1992; 74: 1189-1194.
52. Uy HL, Reasner CA, Samuel MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Grave's disease. Am J Med 1995;99:173-179.